İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - levetiracetam - film-coated tablet - 250 milligram(s) - other antiepileptics; levetiracetam

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - levetiracetam 1000mg - film coated tablet - 1000 mg - active: levetiracetam 1000mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry white 85f18422 povidone purified talc - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - levetiracetam 250mg - film coated tablet - 250 mg - active: levetiracetam 250mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry blue 85f20694 povidone purified talc - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - levetiracetam 500mg - film coated tablet - 500 mg - active: levetiracetam 500mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry yellow 85f32004 povidone purified talc - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - levetiracetam 750mg - film coated tablet - 750 mg - active: levetiracetam 750mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry orange 85f23452 povidone purified talc - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

horizon hospital healthcare pty ltd - levetiracetam -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

horizon hospital healthcare pty ltd - levetiracetam -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

horizon hospital healthcare pty ltd - levetiracetam -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: sodium acetate trihydrate; sodium chloride; water for injections; glacial acetic acid - levetiracetam concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible. use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and, add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; povidone; purified talc; colloidal anhydrous silica; magnesium stearate; titanium dioxide; polyvinyl alcohol; macrogol 3350 - use in epiletpic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary genralisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalised tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).